At the news
? NEUTRALIMPACT 3/10 144 filed Jun 30, 2026 at 16:20 ET
CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is modest relative to the $2.2B market cap and his likely total holdings, but the ~$2.0M cash-out by the CEO is notable in light of Institutional 13F accumulation (8 adds, 1 new) and the lack of recent positive catalysts.
- Insider: Jon Congleton, CEO of Mineralys Therapeutics, filed Form 144 on 6/30/2026 to sell 75,000 shares of common stock.
- Estimated proceeds: ~$1,960,602 at filing (approx. $26.14/share based on recent trade data).
- Shares to be sold were acquired through vesting of RSU awards on 7/10/2024 (24,619 shares), 10/10/2024 (35,954 shares), and 1/10/2025 (14,427 shares).
- Congleton also received a separate RSU award of 75,000 shares on 3/31/2026 and additional shares on 4/13/2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access